Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease (BIOMAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01095744
Recruitment Status : Completed
First Posted : March 30, 2010
Last Update Posted : October 10, 2012
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France

March 12, 2010
March 30, 2010
October 10, 2012
March 2009
May 2012   (Final data collection date for primary outcome measure)
  • PIB-PET imaging of amyloid load [ Time Frame: 0 - 2 months ]
    PET imaging using PIB radio-tracer will give an estimation of regional amyloid load for every patient
  • FDG-PET imaging of glucose metabolism [ Time Frame: 0 - 2 months ]
    PET imaging using 18F-fluorodesoxyglucose (FDG) will give a visualization of regional neuronal metabolism
  • clinical phenotypic assessment [ Time Frame: 0 - 2 months ]
    the clinical evaluation includes a neurologic consulting, a neuropsychologic assessment of cognitive performances, and evaluation of autonomy
  • MRI [ Time Frame: 0 - 2 months ]
    the magnetic resonance imaging will be performed using numerous modalities like T1 weighted sequences for anatomic information, T2 weighted FLAIR and TSE sequences to avoid vascular injuries and T2 GRE to avoid microbleeds, DTI for the diffusion tensor imaging and default mode FMRI, to identify neural networks involved in default concious mode.
  • ApoE gene sequencing [ Time Frame: 0 - 24 months after inclusion ]
    ApoE gene sequencing, will be performed after all samples have been collected. So this may be 0 to 24 month after inclusion.
Same as current
Complete list of historical versions of study NCT01095744 on Archive Site
amyloid and Tau measurements in cerebro-spinal fluid (csf) [ Time Frame: -6 months or +6months arround T0 ]
some patients have a lumbar puncture that allows a direct quantification of CSF amyloid, tau and phospho-tau amounts.This measure is performed in the 6 months following the clinical assessment (at inclusion) and when a former puncture has already been done, it can be used retro-actively up to 6 months before clinical assessment.
Same as current
Not Provided
Not Provided
Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease
Influence of Age on amyloïd Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease Like Posterior Cortical Atrophy (PCA) and Logopenic Progressive Aphasia (LPA)Using Positron Emitting Tomography (PET) Imaging

The first objective is to asses influence of age on amyloid load measured by PET imaging using Pittsburgh B compound (PiB) radio-tracer, in Alzheimer's disease(AD). This will allow the determination of brains age-specific deterioration factors by comparing Early onset AD (EOAD), Late onset AD (LOAD)and atypical focal cortical AD (PCA and LPA). The amount of brain lesions in AD patients is estimated by:

  1. measuring the rate of cortical brain atrophy,
  2. FDG imaging of glucose metabolism reflecting neuronal activity, and
  3. for patients who benefited from a lumbar puncture; Cortical-spinal fluid (CSF) amounts of amyloïd and tau proteins are measured.

Literature data suggests there are different types of AD depending on their age of onset, called EOAD and LOAD. These two categories are distinguished by the localization of brain atrophy : severe and 'posterior' in EOAD and more 'anterior' in LOAD. Neuro-pathologic data suggests some atypical focal cortical atrophy, characterized by a respect of episodic memory, may be classified within EOAD.

PiB-based PET imaging allows the in-vivo visualization and quantification of amyloïd load.

We want to answer the question whether the amount of amyloïd protein may be lower in LOAD than EOAD in patients showing the same level of dementia, and thus identify ageing-specific cognitive disorders and understand witch factors influence etio-pathology of typical and atypical Alzheimer's disease.

Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
DNA sample immortalized blood cell cultures csf aliquots for patients who beneficiated from a lumbar puncture.
Non-Probability Sample
patients have to fulfil criteria for (1)AD with an amnesic syndrome of the media-temporal type, EOAD have lower frequency and (2) and for atypical Ad respecting episodic memory, inaugural language disorder or visual-spatial disorder
  • Alzheimer's Disease
  • Posterior Cortical Atrophy
  • Logopenic Progressive Aphasia
Not Provided
  • EOAD typical AD
    this cohort is constituted with early onset typical AD.
  • LOAD typical
    this group is constituted with late onset typical AD
  • atypical AD
    this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
  • young controls
    under 65
  • old controls
    over 65
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2012
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • AD patients: clinical dementia rating between 0.5 and 2 free and cued recall test (Grober and Buschke) cued-recall < 18/48 and total recall < 40/48
  • atypical AD : i visual-spatial disorder and respect of episodic memory progressive evolution, Balint syndrome ii progressive language disorder constituted of logopenic aphasia respect of episodic memory
  • controls: age over 30 MMSE over or equal to 27 normal neuropsychiatric state for age and education level

Exclusion Criteria:

  • for every patients : psychiatric disorders age under18 absence of social security counter indication to MRI supposed or actual alcoholism or drug addiction pregnancy
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
2008-A00939-46 ( Registry Identifier: IDRCB )
Not Provided
Not Provided
Institut National de la Santé Et de la Recherche Médicale, France
Institut National de la Santé Et de la Recherche Médicale, France
Not Provided
Principal Investigator: Bruno Dubois, professor doctor INSERM U975
Study Chair: marie c sarzin, doctor Inserm U975
Institut National de la Santé Et de la Recherche Médicale, France
February 2012